Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D), but heterogeneity exists across cardiovascular outcome trials (CVOTs). A comprehensive search of PubMed, EMBASE, and Cochrane Library was conducted through November 2024. Eligible CVOTs compared GLP-1 RAs with placebo in T2D patients. The primary outcome was MACE, defined as a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Heterogeneity was assessed using I², τ², and R². Meta-regression analyses evaluated the influence of baseline covariates on cardiovascular benefits of GLP-1 RAs, contingent upon the detection of moderate to substantial heterogeneity (I² ≥ 30%). Sensitivity analyses and GRADE assessments were also performed. Ten trials (67 769 patients; 34 536 receiving GLP-1 RAs) were analyzed. GLP-1 RAs significantly reduced MACE compared with placebo (OR = 0.87, 95% CI: 0.81-0.93, P < 0.001, I² = 48.4%). Cardiovascular death (OR = 0.86, 95% CI: 0.79-0.94, P < 0.001, I² = 22.6%) and all-cause mortality (OR = 0.87, 95% CI: 0.82-0.94, P < 0.001, I² = 17.7%) were also reduced. Meta-regression revealed a greater cardiovascular benefit in patients with higher baseline body mass index (BMI; logOR = -0.098 per kg/m², P = 0.006, R² = 99.98%) and older age (logOR = -0.033 per year, P = 0.023, R² = 75.47%). Sensitivity analyses confirmed the robustness of these findings, with consistent effect sizes and no single trial unduly influencing the results. The certainty of evidence was rated as high for all outcomes based on GRADE criteria. GLP-1 RAs significantly reduce MACE, cardiovascular death, and all-cause mortality in T2D patients. Higher baseline BMI and older age were associated with greater cardiovascular benefit.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ehjcvp/pvaf037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploratory Assessment of Preoperative GLP-1 Receptor Agonists Before Sleeve Gastrectomy: A Retrospective Matched Analysis.
Obes Surg
September 2025
Clinique Mutualiste de Pessac, Pessac, France.
Background: Preoperative treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) before bariatric surgery has not been studied. Therefore, we investigated the impact of neoadjuvant treatment with GLP-1 RAs on weight loss and postoperative outcomes in patients who underwent sleeve gastrectomy for severe obesity.
Method: A retrospective single-center study was conducted between January 2022 and December 2023.
Repurposing glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of depression: A systematic review of preclinical, observational and clinical investigations.
Eur Neuropsychopharmacol
September 2025
Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. Electronic address:
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), currently used for metabolic conditions, have demonstrated potential antidepressant effects via neuromodulatory pathways. This systematic review aims to provide evidence on the antidepressant effects of GLP-1 RAs and elucidate their underlying mechanism of action.
Methods: We examined studies that investigated the effect of GLP-1 RAs on depressive symptoms.
[Effectiveness of GLP-1 receptor agonists in managing patients with type 2 diabetes].
Aten Primaria
September 2025
Hospital Universitario Joan 23, Tarragona, España.
Objective: To evaluate the effectiveness of GLP-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes mellitus and to describe their clinical characteristics.
Design: Retrospective cohort study based on electronic health records. SITE: Health centres of the Primary and Community Care Management (GAPiC) Camp de Tarragona.
Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons.
Dermatol Ther (Heidelb)
September 2025
Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, 40138, Bologna, Bologna, Italy.
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have gained prominence for their efficacy in treating type 2 diabetes and obesity. Recent evidence suggests that their pleiotropic effects-beyond glycemic control and weight loss-include anti-inflammatory, immunomodulatory, and antioxidative effects, which may beneficially support various dermatologic conditions such as psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease. However, GLP-1 RAs are also associated with emerging cutaneous adverse drug reactions, including bullous, exanthematous and vasculitic manifestations, and other rare side effects.
View Article and Find Full Text PDFPreoperative GLP-1 Receptor Agonist Use and Postoperative Outcomes Following Operative Ankle Fracture Repair in Patients With Type 2 Diabetes: A National Database Study.
Foot Ankle Int
September 2025
Department of Orthopaedic Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used in management of type 2 diabetes mellitus (T2DM) and obesity. Beyond glycemic control, these agents may influence orthopaedic outcomes. This study aimed to assess the relationship between preoperative GLP-1 RA use and postoperative complications in T2DM patients undergoing operative ankle fracture repair.
View Article and Find Full Text PDF